Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Payables (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Payables for 13 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Payables rose 61.69% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 61.69% year-over-year, with the annual reading at $653000.0 for FY2025, 57.79% down from the prior year.
  • Payables hit $1.7 million in Q4 2025 for Vistagen Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.7 million in Q3 2022 to a low of $1800.0 in Q4 2021.
  • Historically, Payables has averaged $1.7 million across 5 years, with a median of $1.6 million in 2024.
  • Biggest five-year swings in Payables: plummeted 98.48% in 2021 and later surged 112005.56% in 2022.
  • Year by year, Payables stood at $1800.0 in 2021, then soared by 112005.56% to $2.0 million in 2022, then dropped by 13.92% to $1.7 million in 2023, then plummeted by 40.18% to $1.0 million in 2024, then soared by 61.69% to $1.7 million in 2025.
  • Business Quant data shows Payables for VTGN at $1.7 million in Q4 2025, $2.5 million in Q3 2025, and $1.4 million in Q2 2025.